A B S T R A C T Acid-stimulating action and clearance of pure natural human big gastrin and little gastrin were assessed in four male subjects with inactive duodenal ulcer (DU) disease. Disappearance half-times for HG-17-I after intravenous infusion (5.2 min) or rapid intravenous injection (6.4 min) were six to eight times shorter than those for HG-34-I (41.5 and 37.8 min, respectively).
A B S T R A C T Acid-stimulating action and clearance of pure natural human big gastrin (HG-34-I) and little gastrin (HG-17-I) were assessed in four male subjects with inactive duodenal ulcer (DU) disease. Disappearance half-times for HG-17-I after intravenous infusion (5.2 min) or rapid intravenous injection (6.4 
min)
were six to eight times shorter than those for HG-34-I (41.5 and 37.8 min, respectively).
Studies of clearance of synthetic human little gastrin (HG-17-I) were performed in three of these same four DU subjects, eight additional male DU subjects, and eleven normal male subjects. The disappearance halftime of synthetic HG-17-I averaged 6.2 min in both the DU subjects and the normal subjects. These data suggest that clearance of exogenous gastrin is not altered in patients with DU.
Acid secretion in response to rapid intravenous injection of HG-34-I reached a higher peak and lasted longer than in response to an equimolar dose of HG-17-I; the total response to HG-34-I was about three times that to HG-17-I. During constant intravenous infusion, acid responses to equimolar exogenous doses of the two peptides were similar but the increment in molar concentration of circulating gastrin was six to eight times greater with HG-34-I than with HG-17-I.
Chromatography of serum obtained during infusions of HG-34-I revealed no evidence of conversion to HG-17-I, nor was there any increase in circulating G-34 activity during infusions of HG-17-I.
The increment in serum gastrin concentration required to produce half-maximal stimulation of gastric acid secretion (D50) was estimated in each subject for each gastrin from curves relating acid secretion to change in serum gastrin concentration produced by in-
INTRODUCTION
Two major forms of gastrin, "big" and "little" gastrin, have been identified in human blood (1, 2) . Two linear peptides that behave on molecular sieving like these circulating forms have been isolated from gastrin-secreting tumors and their amino acid sequences have been determined (3, 4) . Human big gastrin (G-34)1 consists of 34 amino acid residues; the single tyrosine residue may be nonsulfated (G-34-I) or sulfated (G-34-II). Human little gastin (G-17) contains 17 amino acid residues and likewise may be either nonsulfated (G-17-I) or sulfated (G-17-II). The COOH-terminal 17-amino-acid sequence of G-34 is identical with G-17. Di- rapidly than G-34 peptides and approximately fivefold higher increments of molar concentrations in serum were required for G-34 than for G-17 peptides to produce equivalent acid-secretory responses.
The purpose of the present investigation was to compare acid-stimulating properties and metabolism of human G-17-I and G-34-I in patients with inactive duodenal ulcer (DU) disease. In addition, the relation between changes in immunoreactive serum gastrin and rates of acid secretion during infusion of these peptides and after a protein meal were compared. Finally, evidence was sought for conversion of G-34 or G-17 to other immunoreactive molecular forms during intravenous infusion of the pure peptides. Additional studies were done to compare the metabolism of synthetic human G-17-I in a larger number of DU and nonulcer subj ects.
METHODS
Gastrins. Pure natural human gastrins, G-17-I and G-34-I, were the generous gifts of Prof. R. A. Gregory and Dr. Hilda Tracy, University of Liverpool. They were purified from a single large gastrin-secreting tumor (3, 4) and were free of contaminating peptides. Gastrin solutions were prepared as previously described (5) . The number of studies performed with G-34-I was limited by the small amount of peptide available (1 mg). Synthetic human G-17-I was obtained from Imperial Chemical Industries, Ltd., Cheshire, England.
Subjects. Four male subjects (mean age 49 yr) with inactive DU were repeatedly studied with natural HG-17-I and HG-34-I. None was taking drugs known to affect gastric secretion. None had complications of peptic ulcer or previous upper gastrointestinal surgery. Clearance of synthetic G-17-I was studied in 3 of these subjects, 8 additional male subjects with inactive DU (mean age 48 yr) and 11 normal male subjects (mean age 32 yr).
All subjects gave voluntary informed consent. The study was approved by the Human Subject Protection Committees at UCLA and VA Wadsworth Hospital Center. Gastrin solutions were administered under Food and Drug Administration IND numbers 9598 and 10-872.
Infusions of human G-17-I and G-34-I. For studies of acid secretion and gastrin clearance, the doses of G-17-I and G-34-I were 6.25, 12.5, 25, 50, 100, and 200 pmol/kg-h. Gastrin solutions were diluted in 27 ml of 0.15 M NaCl and infused intravenously for 90 min by a Harvard syringe pump (Harvard Apparatus Co., Inc., Millis, Mass.). Only one dose of gastrin solution was administered per day. On each study day a nasogastric tube was positioned under fluoroscopic control in the most dependent part of the stomach. Gastric juice was collected by automatic plus manual suction in consecutive 15-min periods during a 30-min basal period, during the 90-min infusion period, and for at least 105 min after discontinuing the infusion or until acid secretion had returned to basal level. Acid concentration was measured by titration of 0.2-ml samples to pH 7.0 with 0.2 N NaOH in an automatic titrator (Radiometer Co., Copenhagen, Denmark) (5). Gastric acid secretion was expressed as highest observed 30-min acid output during each test. Intragastric titration. On a separate day, acid secretion and gastrin release in response to a protein meal were assessed in the four DU subjects tested with G-17-I and G-34-I. The meal consisted of 600 ml 10%o wt/vol peptone (Bacto-peptone, Difco Laboratories, Detroit, Mich.) instilled into the stomach via a nasogastric tube. Acid secretion was measured by automatic intragastric titration (6, 7) . Blood terms of the distance between the protein peak (0%) and the salt peak (100%). Fractions were obtained of 1 ml, and 0.5-ml aliquots were tested for gastrin activity by radioimmunoassay. Standard solutions of G-34-I added to normal serum emerged with the same elution volume (32-36%) as peaks of immunoreactivity obtained by chromatography of serum taken during infusions of G-34-I. The peak elution volumes of standard solutions of G-17-I and serum obtained during G-17-I infusion ranged between 63 and 69%. Gastrin activity in column eluates was measured by radioimmunoassay with a G-34-I standard for the peak emerging before 50% elution volume. The gastrin radioimmunoassay system was sufficiently sensitive to detect gastrin concentrations of 0.25 fmol/ml G-17-I in the final incubation or concentrations greater than 1 fmol/ml in column eluates tested.
Calculations. Disappearance half-time (ti) was calculated for each subject after rapid intravenous injection of human G-17-I and G-34-I and after cessation of intravenous infusions (5). Basal gastrin values were subtracted and the regression of the natural logarithm of increment in serum gastrin vs. time was computed to yield the slope which, with change of sign, is equivalent to the disappearance constant (k,). Disappearance half-time was calculated from the equation: tj = ln2/k..
The infusion period of 90 min was 10-20 times tj for G-17-I, so that during the latter part of the infusion period, serum gastrin concentrations reached equilibrium. However, equilibrium was not achieved during G-34-I infusions, since the infusion period was only 1.5-3 times ti. To predict the serum concentration that would have been achieved if infusions had been prolonged sufficiently, equilibrium steadystate gastrin concentrations were calculated from the equation: A gastrin corrected=A gastrin observed/(1-0.5"); n = infusion time/ti. Volumes of distribution were calculated as previously described (5) , except that corrected steadystate blood concentration of G-34-I was calculated from the observed value at 90 min, as described above.
RESULTS
Serum immunoreactive gastrin during gastrin infusions. Increments in serum gastrin produced by infusions of human G-17-I and G-34-I were linearly related to dose, but equimolar doses of G-34-I produced higher concentrations than did G-17-I (Fig. 1) . Equations for the regression lines (y = equilibrium change in serum gastrin in femtomoles -per milliliter, r = dose in-picomoles per kilogram-hour) were y = 1.15x -1.3, r = 0.999 for G-17-I, and y = 8.34x-24.9, r = 0.994 for G-34-I. The y intercept of the regression lines did not differ significantly from zero. The slope for G-34-I was 7.3 times greater than the slope for G-17-I, indicating slower clearance of G-34-I.
Gastrin half-time studies. Gastrin tj values are shown in Table I G-17-I and G-34-I after 50 pmol/kg rapid intravenous injections are shown in Fig. 2 . After rapid intravenous injection, tj results in the four DU subjects were similar to those obtained after constant infusion (6.4 min for G-17-I and 37.8 min for G-34-I). The slight differences in mean half-times in the figure and table are due to calculation of mean half-time in the figure from mean gastrin concentrations of the four subjects at each time period, compared with averaging individual half-times in the table. In addition, after infusion of synthetic human G-17-I, the mean half-times in the four DU patients were similar to those obtained in the larger group of ulcer and normal subjects (Table I) . Mean volumes of distribution of natural human G-17-I and G-34-I measured after infusions or rapid i.v. injections were similar and ranged from 10 to 14% body weight in the four ulcer patients. Mean calculated spaces of distribution of synthetic G-17-I in the larger group of normal and DU subjects were similar, 17% and 13%, respectively.
The mean ratios of serum half-times (G-34/G-17) after infusions (8.0) and rapid injections (5.9) agreed reasonably well with the ratio of slopes calculated from regression of increment of serum gastrin on dose (7.3). These three independent estimates indicate that G-17-I is cleared from the circulation about six to eight times more rapidly than G-34-I.
Acid secretion rates vs. exogenous dose and change in serum gastrin. Highest observed 30-min acid outputs during the 90-min infusions of human G-17-I and G-34-I in the four DU subjects are shown in Fig. 3 . Responses were not significantly different after equivalent molar doses.
Mean acid secretory responses, normalized as a percentage of the highest observed response during each infusion, in the four DU subjects, are shown in Fig. 4 . The acid secretory responses to G-17-I reached a plateau within 60 min after starting the infusion. During infusion of G-34-I, acid secretion began promptly but had not reached a peak plateau 90 min after starting the infusion, and did not return to preinjection level 105 min after discontinuing the infusion. Acid secretory half-times, calculated from individual tests after G-17-I, ranged from 19.5 to 27.5 min (24.3±1.8 min), and after Mean acid secretory responses to rapid iv.. injection of 50 pmol/kg of G-17-I and G-34-I in the four DU subjects are shown in Fig. 5 . The response to G-17-I reached a peak during the first two 15-min periods and fell to basal rates within 60 min. After G-34-I injection, secretion increased promptly but the peak rate occurred later, was greater than that achieved with G-17-I, and persisted above basal rates for 2J h. Total secretory response to G-34-I was approximately three times greater than to G-17-I.
In contrast, there was a marked difference in potency of circulating human G-17-I and G-34-I as stimulants of acid secretion. To produce the same rate of acid secre- tion, approximately four to eight times greater increment in the molar concentration of G-34-I than in G-17-I was required (Fig. 6 ). Exact ratios could not be calculated because the dose-response curves were not parallel. Chromatography of serum obtained during gastrin infusions. In all four DU subjects, serum obtained 90 min after onset of G-34-I infusion yielded a single peak of immunoreactive gastrin, recovered with the characteristic elution volume of G-34-I. Less than 1% of gastrin immunoreactivity was recovered in the G-17-I region. Similarly, 92% (range 81-100%) of gastrin immunoreactivity was recovered in the G-17-I region during infusions of G-17-I. The remaining 8% eluting in the G-34-I region (16 fmol/ml) did not differ significantly from mean recovery in this region in basal serum (17 fmol/ml). Thus, no evidence was obtained for significant conversion of G-17-I or G-34-I into the other molecular form during infusion of either pure peptide.
Response to peptone meals. Acid secretion rates 30-60 min after introduction of peptone meals averaged 55% of peak G-17-I-stimulated secretory rates, compared with 6% in the basal period. Increases in total serum gastrin activity in unfractionated serum at 30 min and 60 min after the meal were 60 and 57 pg equivalents G-17-I/ml, respectively (Table II) . In serum obtained during the basal period and 30 and 60 min after the meal, specific molar increases in serum G-17 and G-34 were measured by column chromatography and radioimmunoassay of peaks with appropriate standards. Recovery of 100 fmol G-34-I added to 1 ml basal serum or 1 ml 60-min-postprandial serum was assessed by column chromatography. Recovery averaged 65±12% in basal and 66±9% in 60-min-postprandial serum. Recovery of 50 fmol G-17-I added to the same serum specimens averaged 97+8% and 87±6%. Mean increase in G-34 over basal was 44 fmol/ml at both 30 and 60 min, while mean increase in G-17 was 18 fmol/ml at 30 min and 14 fmol/ml at 60 min (Table II) . The relative contributions of G-17 and G-34 to acid secretion stimulated by the peptone meal were estimated from mean molar increments in G-17 and G-34 30 and 60 min after the meal, compared with molar increments in circulating G-17-I and G-34-I required to produce half-maximal secretory responses (DD) during infusions of pure gastrins (Table III) . Estimated mean total circulating activity represented by G-17 and G-34 were 0.88 and 0.67 X Duo, respectively, at 30 min, and 0.72 and 0.65 X Do at 60 min. Mean acid secretion was 55% of peak acid output during the 30-60-min time period. At both 30 and 60 min, G-17 appeared to contribute the majority of acid-stimulating activity as estimated from multiples of D5o present in the serum. The fraction of acid-stimulating activity contributed by G-17 was estimated as 62% when calculated from individual subjects or as 55% when calculated from mean data.
DISCUSSION
The results of the present studies in DU subjects indicate that: (a) equimolar infusions of human G-17-I and G-34-I produced similar acid secretory responses; (b) circulating G-17-I was a more potent stimulant of gastric acid secretion than G-34-I; (c) the secretory and serum half-times of G-34-I were significantly longer than G-17-I; (d) serum half-time of G-17-I was not different in DU and controls; (e) there was no ap- G-34T  G-17t   T  G-34  G-17  T  G-34  G-17 pg eq/ml fmol/ml Pg/eq/ml fmol/ml pg/eq/ml fmol/ml
